12:00 AM
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GFT505: Phase IIb started

Genfit began the double-blind, placebo-controlled, international, pivotal Phase IIb GFT505-212-7 trial to evaluate once-daily oral GFT505 for 52 weeks in about 270 diabetic and non-diabetic NASH patients. The trial will evaluate an 80 mg dose for...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >